Study guide
11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)
C-OBE Obstetric Emergencies Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Maternal Assessment, Risk Stratification & Early Warning Systems
1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification 1.2 Dynamic Antepartum & Intrapartum Risk Assessment 1.3 Maternal Early Warning Systems (MEWS/MEWT) & Critical Triage Physical Assessment 1.4 Alliance for Innovation on Maternal Health (AIM) Safety Bundles & Emergency Readiness
2 Chapter 2: Obstetric Hemorrhage — Etiology, Assessment & Uterotonics
2.1 Postpartum Hemorrhage Etiology (4 T's) & Quantitative Blood Loss (QBL) 2.2 Uterotonic Pharmacology & Stepwise Administration Protocols 2.3 Tranexamic Acid (TXA) Protocols & Hemorrhage Timing
3 Chapter 3: Obstetric Hemorrhage — Mechanical Interventions, Placental Disorders & Transfusion
3.1 Intrauterine Tamponade Balloons, Compression Sutures & Surgical Hemostasis 3.2 Ectopic Pregnancy, Placenta Previa, Accreta Spectrum (PAS), Abruption & Vasa Previa 3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)
4 Chapter 4: Hypertensive Disorders of Pregnancy & Preeclampsia with Severe Features
4.1 Classification & Spectrum of Hypertensive Disorders of Pregnancy 4.2 Preeclampsia with Severe Features: Pathophysiology & End-Organ Damage 4.3 Diagnostic Evaluation, Laboratory Triggers & Fetal Surveillance in Preeclampsia
5 Chapter 5: Hypertensive Crisis, Eclampsia & Magnesium Sulfate Therapy
5.1 Acute Severe Hypertension & First-Line Antihypertensive Protocols 5.2 Eclampsia Recognition, Seizure Management & Airway Protection 5.3 Magnesium Sulfate Neuroprotection/Seizure Prophylaxis Protocols, Monitoring & Toxicity Reversal 5.4 HELLP Syndrome & Hepatic Crisis Management
6 Chapter 6: Maternal Resuscitation, Cardiac Arrest & Perimortem Cesarean
6.1 Maternal ACLS Modifications & Cardiopulmonary Resuscitation Physiology 6.2 Etiologies of Maternal Arrest & Structured Emergency Response 6.3 Perimortem Cesarean Delivery (PMCD / Resuscitative Hysterotomy)
7 Chapter 7: Amniotic Fluid Embolism & Maternal Shock States
7.1 Amniotic Fluid Embolism (AFE): Pathophysiology & Clinical Presentation 7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE 7.3 Maternal Shock States: Hemorrhagic, Distributive, Cardiogenic & Obstructive
8 Chapter 8: Acute Intrapartum Delivery Emergencies
8.1 Shoulder Dystocia: Recognition, Timing & Primary HELPERR Sequence 8.2 Advanced Shoulder Dystocia Maneuvers & Neonatal Brachial Plexus Injury Prevention 8.3 Umbilical Cord Prolapse Recognition & Emergent Decompression Protocols
9 Chapter 9: Uterine Inversion, Malpresentation & Obstetric Trauma
9.1 Acute Uterine Inversion: Recognition, Tocolysis & Manual/Surgical Reduction 9.2 Emergency Vaginal Breech Extraction & Head Entrapment Maneuvers 9.3 Maternal Trauma: Primary/Secondary Survey, Placental Abruption & Fetomaternal Hemorrhage
10 Chapter 10: Maternal Sepsis, Intraamniotic Infection & Severe Infections
10.1 Maternal Sepsis: Physiological Criteria, S.O.S. Score & omSOFA 10.2 The Maternal Sepsis Hour-1 Bundle & Fluid/Vasopressor Optimization 10.3 Intraamniotic Infection (Triple I / Chorioamnionitis) & Severe Endometritis 10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections
11 Chapter 11: Endocrine, Cardiovascular, Respiratory & Neurologic Emergencies
11.1 Diabetic Ketoacidosis (DKA), Maternal Hypoglycemia & Endocrine Resuscitation in Pregnancy 11.2 Peripartum Cardiomyopathy (PPCM), Acute Heart Failure, Acute Coronary Syndromes & Maternal Arrhythmias 11.3 Status Asthmaticus, Pulmonary Edema & ARDS in Pregnancy 11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)
12 Chapter 12: Thromboembolism, Hepatorenal Disorders & Toxicologic Emergencies
12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation 12.2 Acute Fatty Liver of Pregnancy (AFLP / Swansea Criteria) & Acute Kidney Injury 12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration
13 Chapter 13: Obstetric Anesthesia Emergencies & Critical Complications
13.1 High Spinal / Total Spinal Anesthesia & Aspiration Pneumonitis 13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol 13.3 Post-Dural Puncture Headache (PDPH), Epidural Hematoma & Abscess 13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol
14 Chapter 14: Professional Practice, Team Communication, Debriefing & Health Equity
14.1 Crisis Resource Management (CRM), TeamSTEPPS & Structured Communication 14.2 Multidisciplinary Emergency Debriefing, Morbidity & Mortality, and Systems Learning 14.3 Perinatal Racial/Ethnic Disparities, Implicit Bias Mitigation & Respectful Maternity Care 14.4 Legal, Ethical, Documentation & EMTALA Standards in Obstetric Emergencies
11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)
Key Takeaways Explain This Topic AI
Status epilepticus (continuous seizure activity >5 minutes or recurrent seizures without return to baseline) is a life-threatening neuro-obstetric emergency requiring immediate abortive therapy with IV Lorazepam (4 mg over 2 minutes), followed by non-sedating IV antiseizure loads (Levetiracetam 60 mg/kg or Fosphenytoin 20 mg PE/kg).
Clinicians must rapidly distinguish status epilepticus from eclampsia; while eclampsia is treated with intravenous magnesium sulfate (4–6 g loading bolus followed by 1–2 g/h) and blood pressure control, status epilepticus in an epileptic patient requires standard antiepileptic drugs (and both should be given simultaneously if the diagnosis is ambiguous).
Acute ischemic stroke during pregnancy or the puerperium is not a contraindication to intravenous recombinant tissue plasminogen activator (rtPA / alteplase) within 4.5 hours or mechanical endovascular thrombectomy (EVT); urgent neuroimaging (non-contrast CT or MRI with DWI) with fetal shielding must never be delayed.
Cerebral Venous Sinus Thrombosis (CVST) classically presents with severe progressive headache, papilledema, and seizures; diagnosis is confirmed via MRV or CTV, and full therapeutic anticoagulation (LMWH or UFH) is the mandatory first-line therapy even in the presence of secondary hemorrhagic venous infarction.
Last updated: August 2026
Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)
Neurological emergencies in pregnancy and the puerperium present unique diagnostic and therapeutic challenges. Pregnancy induces profound neuroendocrine alterations, expanded intravascular volume, and marked hypercoagulability that significantly increase the risk of vascular and convulsive crises. Rapid diagnosis, prompt pharmacological intervention, and appropriate multidisciplinary collaboration between obstetrics, neurology, and critical care are essential to prevent permanent maternal neurological disability and fetal demise.
- 1. Status Epilepticus: Definition & Neuro-Obstetric Pathophysiology
- Definition
Status Epilepticus (SE) is defined as continuous, unprovoked seizure activity lasting ≥ 5 minutes , or two or more distinct seizure episodes without complete recovery of consciousness between events (Neurocritical Care Society and ILAE definitions). This definition reflects the point at which normal endogenous mechanisms fail to terminate seizure activity and irreversible neuronal injury begins. +---------------------------------------------------------------------------------------------------+
- | SYSTEMIC & FETAL IMPACT OF STATUS EPILEPTICUS |
- | |
- | • MATERNAL SYSTEMIC COMPLICATIONS: |
- | - Phase 1 (Hyperadrenergic / Compensated, 0–30 min): Severe hypertension, tachycardia, |
- | hyperthermia, massive cerebral glucose consumption, and profound lactic acidosis. |
- | - Phase 2 (Decompensated, >30–60 min): Systemic hypotension, cerebral hypoperfusion, |
- | hypoglycemia, rhabdomyolysis, hyperkalemia, acute kidney injury, and pulmonary edema. |
- | |
- | • FETAL PATHOPHYSIOLOGY: |
- | - Continuous violent maternal myometrial contractions and massive catecholamine release induce |
- | intense uterine artery vasoconstriction, reducing uteroplacental blood flow by up to 70%. |
- | - Maternal hypoxemia, hyperthermia, and lactic acidosis cross the placenta, triggering severe |
- | sustained fetal bradycardia, profound asphyxia, placental abruption, or intrauterine demise. |
- +---------------------------------------------------------------------------------------------------+
2. Stepwise Pharmacological Management of Status Epilepticus +---------------------------------------------------------------------------------------------------+
- | STATUS EPILEPTICUS EMERGENCY PROTOCOL |
- | |
- | PHASE 1: STABILIZATION & BEDSIDE EVALUATION (0 TO 5 MINUTES) |
- | • Maintain airway, 100% supplemental O2, place patient in **left lateral tilt** (relieve IVC). |
- | • Check **STAT Capillary Blood Glucose** (if hypoglycemic: 50 mL D50W IV + 100 mg Thiamine IV). |
- | • Establish 2 large-bore IV lines; send STAT CBC, CMP, Magnesium, Lactate, AED drug levels. |
- | |
- | PHASE 2: EMERGENT INITIAL ABORTIVE THERAPY (5 TO 10 MINUTES) |
- | • FIRST-LINE AGENT: **Intravenous Lorazepam (Ativan) 4 mg IV push over 2 minutes**. |
- | - If seizures continue after 5 to 10 minutes, repeat once (total max 8 mg). |
- | • ALTERNATIVE (IF NO IV ACCESS): **Intramuscular Midazolam 10 mg IM** (for weight >40 kg) OR |
- | **Rectal Diazepam 10 to 20 mg PR** OR **Intranasal Midazolam 10 mg**. |
- | |
- | PHASE 3: URGENT SECOND-LINE ANTISEIZURE INFUSION (10 TO 20 MINUTES) |
- | • Administer immediately following benzodiazepine to prevent seizure recurrence: |
- | 1. **Intravenous Levetiracetam (Keppra): 60 mg/kg IV (max 4,500 mg)** infused over 10 minutes. |
- | - First-line preferred agent in pregnancy: non-sedating, zero teratogenicity concerns in |
- | acute rescue, and no drug-drug interactions or hepatic enzyme induction. |
- | 2. **Intravenous Fosphenytoin: 20 mg PE/kg IV (max 1,500 mg PE)** at up to 150 mg PE/min. |
- | - Requires continuous ECG and blood pressure monitoring (risk of hypotension/arrhythmias). |
- | 3. **Intravenous Sodium Valproate: 40 mg/kg IV (max 3,000 mg)** over 10 minutes. |
- | - Highly effective, but generally avoided in 1st trimester due to neural tube defects; |
- | acceptable in life-threatening status when other agents fail or in the puerperium. |
- | |
- | PHASE 4: REFRACTORY STATUS EPILEPTICUS (>20 TO 30 MINUTES) |
- | • Transfer to ICU, perform immediate **Endotracheal Intubation**, and initiate Continuous |
- | Electroencephalography (cEEG) monitoring. |
- | • General Anesthetic Continuous Infusions (titrate to burst suppression on cEEG): |
- | - **Propofol:** 2 mg/kg IV bolus, then 2 to 10 mg/kg/hour continuous infusion. |
- | - **Midazolam:** 0.2 mg/kg IV bolus, then 0.05 to 2.0 mg/kg/hour continuous infusion. |
- | - **Ketamine:** 1.5 to 3.0 mg/kg IV bolus, then 1.0 to 5.0 mg/kg/hour infusion. |
- +---------------------------------------------------------------------------------------------------+
- 3. Differential Diagnosis: Status Epilepticus vs Eclampsia
Distinguishing epileptic status epilepticus from eclamptic seizures is crucial because their definitive pharmacotherapies and delivery pathways differ fundamentally.
Diagnostic Parameter Primary Epileptic Seizure / Status Eclampsia
Underlying Etiology Preexisting epilepsy, AED non-compliance, structural CNS lesion Preeclampsia-associated cerebral vasospasm, endothelial leak, loss of cerebral autoregulation
Gestational Age Any gestational age or postpartum > 20 weeks of gestation or up to 4–6 weeks postpartum
Blood Pressure Normal or transient secondary elevation during convulsion Markedly elevated (≥140/90 mmHg, often ≥160/110 mmHg)
Preeclampsia Markers Absent (normal labs, no proteinuria) Present (proteinuria, elevated transaminases, thrombocytopenia)
Seizure Duration Often prolonged (>5 min) or continuous without recovery Typically self-limited (1–2 min), generalized tonic-clonic
Definitive Treatment IV Benzodiazepines + IV Levetiracetam / Fosphenytoin IV Magnesium Sulfate (4–6 g load + 1–2 g/h) + Antihypertensives
Response to Magnesium Magnesium is INEFFECTIVE for stopping epileptic SE Highly effective in terminating and preventing recurrent eclampsia
Delivery Strategy Delivery NOT required unless persistent fetal compromise Mandatory Delivery once maternal stabilization is achieved
The Ambiguous Presentation Rule: If a pregnant patient at ≥20 weeks gestation presents with active generalized convulsive seizures of unknown etiology or with elevated blood pressure, ADMINISTER BOTH INTRAVENOUS MAGNESIUM SULFATE (4–6 g load) AND INTRAVENOUS LORAZEPAM (4 mg) simultaneously without delay. Magnesium treats potential eclampsia, while lorazepam aborts epileptic status.
4. Acute Stroke in Pregnancy & Puerperium
Pregnancy increases the risk of stroke 3-fold , with an overall incidence of approximately 30 per 100,000 deliveries. Over 75% of pregnancy-associated strokes occur in the late third trimester or the first 6 weeks postpartum .
Acute Ischemic Stroke (AIS)
Etiologies: Cardioembolism (PPCM, paradoxical embolism via patent foramen ovale [PFO], mechanical valve thrombosis), arterial dissection (cervical internal carotid or vertebral artery dissection), Reversible Cerebral Vasoconstriction Syndrome (RCVS), antiphospholipid syndrome (APS), or preeclampsia-associated endothelial thrombosis.
Emergency Neuroimaging:
STAT Non-Contrast Head CT or Brain MRI with Diffusion-Weighted Imaging (DWI) .
Fetal Radiation Safety: Fetal radiation exposure from a maternal head CT with abdominal pelvic shielding is <0.005 mGy (the threshold for fetal teratogenesis or microcephaly is >50 mGy). DIAGNOSTIC NEUROIMAGING MUST NEVER BE WITHHELD OR DELAYED DUE TO PREGNANCY. +---------------------------------------------------------------------------------------------------+
- | REVASCULARIZATION THERAPIES IN PREGNANCY AIS |
- | |
- | 1. INTRAVENOUS THROMBOLYSIS (IV rtPA / ALTEPLASE): |
- | • Dose: **0.9 mg/kg IV (max 90 mg)**; 10% given as bolus over 1 min, remainder over 60 min. |
- | • Time Window: Within **4.5 hours of symptom onset** (last known normal). |
- | • Pregnancy Safety: **Pregnancy is NOT a contraindication to IV rtPA for disabling stroke** |
- | (AHA/ASA Stroke Guidelines). |
- | • Molecular Pharmacology: Alteplase is a large macromolecule (~59 kDa) that **DOES NOT CROSS |
- | THE PLACENTA**. Maternal neurological rescue far outweighs the slight (~1%) risk of |
- | placental abruption or uterine bleeding. |
- | |
- | 2. ENDOVASCULAR MECHANICAL THROMBECTOMY (EVT): |
- | • Indicated for Large Vessel Occlusion (LVO) of the Internal Carotid Artery (ICA) or proximal |
- | Middle Cerebral Artery (MCA M1) within **6 to 24 hours of onset**. |
- | • Highly safe and effective in pregnancy; minimal radiation with pelvic lead shielding. |
- +---------------------------------------------------------------------------------------------------+
- Hemorrhagic Stroke (Intracerebral Hemorrhage & Subarachnoid Hemorrhage)
Etiologies: Ruptured intracranial berry aneurysm (responsible for >50% of pregnancy SAH), Arteriovenous Malformations (AVMs), and severe preeclampsia/eclampsia-induced intracerebral hemorrhage.
Clinical Triad: Sudden "thunderclap" headache, meningismus/neck stiffness, and acute altered level of consciousness.
Management:
Immediate blood pressure control: IV Nicardipine infusion (5–15 mg/h) or IV Labetalol to maintain systolic blood pressure strictly between 130 and 150 mmHg .
STAT neurosurgical consultation for emergency endovascular coiling or surgical clipping of aneurysm/AVM.
Emergent cesarean delivery is indicated if maternal herniation is imminent or for viable gestational age under simultaneous neurosurgical-obstetric intervention.
5. Cerebral Venous Sinus Thrombosis (CVST)
Cerebral Venous Sinus Thrombosis (CVST) is the thrombosis of the dural venous sinuses (superior sagittal sinus, transverse sinus, sigmoid sinus) or cortical veins. The puerperium represents the highest-risk period in a woman's lifetime, with an incidence of 10 to 12 per 100,000 deliveries (representing a 10-fold increase over the non-pregnant baseline). +---------------------------------------------------------------------------------------------------+
- | CVST CLINICAL PRESENTATION & DIAGNOSIS |
- | |
- | • CLINICAL PRESENTATION: |
- | - **Severe, Persistent Headache (>90% of cases):** Worsens in supine position, progresses over |
- | days, refractory to simple analgesics. |
- | - **Signs of Intracranial Hypertension:** Papilledema, visual obscurations, diplopia (CN VI). |
- | - **Focal Neurological Deficits & Seizures (40%):** Focal motor weakness, aphasia, or focal |
- | seizures with secondary generalization. |
- | - **Altered Mental Status / Encephalopathy:** In severe thrombosis of deep cerebral veins. |
- | |
- | • DIAGNOSTIC NEUROIMAGING: |
- | - **Magnetic Resonance Venography (MRV) with Brain MRI (DWI/T2* GRE)** is the gold standard. |
- | - **CT Venography (CTV):** Rapid alternative; demonstrates the classic **"Empty Delta Sign"** |
- | (non-enhancing triangular thrombus within the contrast-filled superior sagittal sinus). |
- +---------------------------------------------------------------------------------------------------+
- The Mandatory Anticoagulation Protocol: The Venous Infarction Paradox
Venous sinus thrombosis causes severe upstream venous congestion, leading to brain edema and secondary hemorrhagic venous infarction in 30% to 40% of cases . +---------------------------------------------------------------------------------------------------+
- | THE CRITICAL CLINICAL RULE IN CVST MANAGEMENT |
- | |
- | • **FULL THERAPEUTIC ANTICOAGULATION IS MANDATORY AS FIRST-LINE THERAPY, EVEN IN THE PRESENCE |
- | OF PRE-EXISTING INTRACRANIAL HEMORRHAGE / VENOUS HEMORRHAGIC INFARCTION!** |
- | |
- | • CLINICAL RATIONALE: |
- | - Intracranial bleeding in CVST is caused by severe backward venous hypertension resulting |
- | from occluded sinus outflow. |
- | - Anticoagulation arrests thrombus propagation, promotes recanalization, and restores venous |
- | drainage, which paradoxically **decreases venous pressure and halts further hemorrhage**. |
- | - Withholding anticoagulation out of fear of bleeding leads to catastrophic clot extension, |
- | massive venous infarction, herniation, and death. |
- | |
- | • PHARMACOLOGICAL REGIMEN: |
- | - Initial Therapy: **Therapeutic Low-Molecular-Weight Heparin (Enoxaparin 1 mg/kg SC Q12H)** |
- | OR **Intravenous Unfractionated Heparin (UFH)** titrated to target aPTT 60–85 seconds. |
- | - Postpartum Maintenance: Continue therapeutic anticoagulation (LMWH or Warfarin, target |
- | INR 2.0–3.0) for a minimum of **3 to 6 months** (or lifelong if unprovoked / severe APS). |
- | - Seizure Prophylaxis: Add **Levetiracetam (Keppra 500–1,000 mg PO/IV BID)** in patients with |
- | focal deficits, seizures, or supratentorial parenchymal lesions. |
- +---------------------------------------------------------------------------------------------------+